Can AI replace 60% of pharmaceutical r&d by designing and testing new drugs in silico using generative chemistry and predictive toxicity models ?

Deep learning models like AlphaFold have already revolutionized protein folding. Generative AI is now proposing novel molecules with promising binding affinities—raising the question of when AI can fully take over drug discovery.

---

As of 2024, AI-driven generative chemistry and predictive toxicity models have made significant strides in accelerating early-stage drug discovery, enabling rapid in silico design and screening of molecular candidates. Techniques such as multi-objective optimization with reinforcement learning (e.g., REINVENT or MolGen) and transformer-based models (e.g., AlphaFold2-informed docking) can propose novel structures with favorable binding affinities and reduced off-target risks. However, no published source supports the claim that these tools can autonomously replace 60% of traditional pharmaceutical R&D—clinical trials, regulatory filings, and large-scale human trials remain human-led and data-intensive. Current industry practice emphasizes AI as a force multiplier in hit discovery and lead optimization rather than a wholesale replacement of R&D workflows.

— Enriched May 10, 2026 · Source: McKinsey & Company — https://www.mckinsey.com/industries/life-sciences/our-insights/artificial-intelligence-in-pharmaceutical-drug-discovery